Serious TEAEs and Serious Infections
Serious TEAEs and serious infections are also evaluated against the filgotinib and GS-829845 exposures and no exposure-driven patterns were present based on the safety data up to Week 52 (Supplementary Figure 1).
Overall, the exposure-safety relationships for either filgotinib and GS-829845 demonstrate no trend toward increasing incidence of common TEAEs, common laboratory abnormalities, serious TEAEs, or serious infections with increasing exposure.